PCSK9 and diabetes mellitus: A comprehensive meta-analysis of PCSK9 inhibitors has confirmed the drug’s safety profile, including its effects on neurocognitive adverse events, myalgia, new onset or worsening of pre-existing diabetes, elevated levels of creatine kinase, and the increase in alanine or aspartate aminotransferase having no significant impact (47).